Home
Products
Learn
About
Pricing
Log In
IMR
Asset Logo

Imricor Medical Systems Inc.

🇦🇺 ASX

📈 HIGH PRICE GROWTH

🩺 HEALTH CARE

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

+ 14.34%
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

7
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm develops MRI-compatible products for cardiac catheter ablation procedures. The Vision-MR Ablation Catheter is the Company’s prime product offering, specifically designed to work under real-time MRI guidance. Its other products include Advantage-MR EP Recorder/Stimulator System, the Vision-MR Diagnostic Catheter and Vision-MR Dispersive Electrode. Advantage-MR EP Recorder/Stimulator System provides technology that allows the physician to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The company sells its capital and consumable products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.

📈 Performance

Price History

-1.72%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$1.43

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in IMR

7

📊 Total Capital Earnings

$15K

🔃 Average investment frequency

31 weeks

💵 Average investment amount

$1,209

Last time a customer invested in IMR

2 days
IMR investor breakdown
💵 Income of investors

More than 200k

17%

150k - 200k

100k - 150k

8%

50k - 100k

33%

Less than 50k

25%
👶 Age of investors

18 - 25

26 - 34

43%

35 - 90

57%
🙋 Legal gender of investors

Female

14%

Male

86%

Pearlers who invest in IMR also invest in...

Neuren Pharmaceuticals Limited

NEU

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

🙌 Performance (5Yr p.a)

197.29%

📊 Share price

$10.81 AUD

📦 LOGISTICS

Find Out More

DroneShield Ltd. engages in the development and commercialisation of hardware and software technology for drone detection and security. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-06-22. The company provides artificial intelligence-based platforms for protection against advanced threats, such as drones and autonomous systems. The company offers customers bespoke counter-drone (or counter-UAS) and electronic warfare solutions and off-the-shelf products designed to suit a variety of terrestrial, maritime, or airborne platforms. The Company’s products include DroneGun Tactical, DroneGun MKIII, DroneSentry, DroneSentry-C2, DroneSentry-X, RfPatrol and DroneSim among others. The DroneGun Tactical is an unmanned aerial systems (UAS) countermeasure designed for two-hand operation and long-range defeat. RfPatrol is a passive/non-emitting wearable UAS detection device. The Company’s capabilities include C-UAS, C-UxS Training, and Electronic Warfare.

🙌 Performance (5Yr p.a)

162.00%

📊 Share price

$0.91 AUD

🚀 AEROSPACE & DEFENSE

Alcidion Group Ltd. engages in the development and provision of healthcare software products marketed under the Miya, Patientrack, Smartpage and ExtraMed brands. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-06-24. The firm's principal activities include the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of selected healthcare software products from its strategic partners and the delivery of product implementation, product support and maintenance, systems integration, and data analysis services to healthcare customers in Australia, New Zealand, and the United Kingdom. Its product, Miya Precision, is a smart clinical solution based on a FHIR-event platform that facilitates multiple clinical and operational applications. The firm's other products include Smartpage, Patientrack, and Silverlink PCS. Smartpage is an advanced smartphone and Web-based system for hospital communication and task management, addressing the requirements of both clinical and non-clinical users.

🙌 Performance (5Yr p.a)

-8.47%

📊 Share price

$0.08 AUD

🩺 HEALTH CARE

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6698.35m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

🙌 Performance (5Yr p.a)

10.52%

📊 Share price

$132.40 AUD

🇦🇺 AUSTRALIA

💸 FINANCIALS

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

🙌 Performance (5Yr p.a)

9.60%

📊 Share price

$10.76 AUD

📈 HIGH PRICE GROWTH

🇦🇺 EX AUSTRALIA

Want more shares? Try these...

IMRAW

Compare
Add to watchlist